Country / Location Selection
GeneTex has collaborated with an outside lab to create the key recombinant reagents for development of a lateral flow-based neutralization assay for SARS-CoV-2. These components are designed to allow detection of neutralizing antibodies in a sample by demonstrating decreased interaction between the viral spike protein receptor-binding domain (RBD) and the ACE2 receptor in a lateral flow assay (LFA) format (Figure 1). Since these antibodies and proteins are recombinant, they are easily scalable for commercial purposes.
Figure 1. (A) SARS-CoV-2 neutralizing antibody interferes with the binding of ACE2 and spike RBD proteins. The signal intensity of the test line (T) decreases due to competition by the neutralizing antibody, while the control line (C) demonstrates a valid test. (B) The design and structure of the assay and its components.
Neutralizing Antibody: Spike RBD antibody [HL1002] (GTX635791) / C Line: Detector: Colloidal gold-conjugated human ACE2 (ECD) protein (GTX135683-pro) / Capture: Anti-human ACE2 (ECD) antibody (GTX635897) / T Line: Detector: Colloidal gold-conjugated human ACE2 (ECD) protein (GTX135683-pro) / Capture: SARS-CoV-2 Spike RBD protein
Reagents for Neutralization Assay | |||||
|